134 related articles for article (PubMed ID: 15780569)
21. Increasing the number of biopsies increases the concordance of Gleason scores of needle biopsies and prostatectomy specimens.
Divrik RT; Eroglu A; Sahin A; Zorlu F; Ozen H
Urol Oncol; 2007; 25(5):376-82. PubMed ID: 17826653
[TBL] [Abstract][Full Text] [Related]
22. Prostate-specific antigen velocity and prostate cancer gleason grade and stage.
Pinsky PF; Andriole G; Crawford ED; Chia D; Kramer BS; Grubb R; Greenlee R; Gohagan JK
Cancer; 2007 Apr; 109(8):1689-95. PubMed ID: 17330856
[TBL] [Abstract][Full Text] [Related]
23. Prediction of potentially insignificant prostate cancer in men undergoing radical prostatectomy for clinically organ-confined disease.
Miyake H; Sakai I; Harada K; Hara I; Eto H
Int J Urol; 2005 Mar; 12(3):270-4. PubMed ID: 15828954
[TBL] [Abstract][Full Text] [Related]
24. [Evaluation for clinical staging parameters of prostate neoplasm].
Zhong CY; Liu M; Zhang LQ; Wan B
Zhonghua Nan Ke Xue; 2003 Apr; 9(2):100-2. PubMed ID: 12749126
[TBL] [Abstract][Full Text] [Related]
25. Side-specific factors associated with extracapsular extension and seminal vesicular invasion in men undergoing open radical retropubic prostatectomy.
Sankin A; Tareen B; Lepor H
Prostate Cancer Prostatic Dis; 2009; 12(2):204-8. PubMed ID: 19238170
[TBL] [Abstract][Full Text] [Related]
26. Prognostic factors of persistently detectable PSA after radical prostatectomy.
Naselli A; Introini C; Andreatta R; Spina B; Truini M; Puppo P
Int J Urol; 2009 Jan; 16(1):82-6. PubMed ID: 19054168
[TBL] [Abstract][Full Text] [Related]
27. Percentages of positive cores, cancer length and Gleason grade 4/5 cancer in systematic sextant biopsy are all predictive of adverse pathology and biochemical failure after radical prostatectomy.
Suekane S; Noguchi M; Nakashima O; Yamada S; Kojiro M; Matsuoka K
Int J Urol; 2007 Aug; 14(8):713-8. PubMed ID: 17681061
[TBL] [Abstract][Full Text] [Related]
28. Endothelin-1: a predictor of extracapsular extension in clinically localized prostate cancer?
Menard J; Durlach A; Barbe C; Joseph K; Lorenzato M; Azemar MD; Perez T; Birembault P; Staerman F
BJU Int; 2011 Jul; 108(2 Pt 2):E104-9. PubMed ID: 21091977
[TBL] [Abstract][Full Text] [Related]
29. Micro-focal prostate cancer: a comparison of biopsy and radical prostatectomy specimen features.
Boccon-Gibod LM; Dumonceau O; Toublanc M; Ravery V; Boccon-Gibod LA
Eur Urol; 2005 Dec; 48(6):895-9. PubMed ID: 16125298
[TBL] [Abstract][Full Text] [Related]
30. Multigene methylation analysis for detection and staging of prostate cancer.
Enokida H; Shiina H; Urakami S; Igawa M; Ogishima T; Li LC; Kawahara M; Nakagawa M; Kane CJ; Carroll PR; Dahiya R
Clin Cancer Res; 2005 Sep; 11(18):6582-8. PubMed ID: 16166436
[TBL] [Abstract][Full Text] [Related]
31. A single microfocus (5% or less) of Gleason 6 prostate cancer at biopsy--can we predict adverse pathological outcomes?
Thong AE; Shikanov S; Katz MH; Gofrit ON; Eggener S; Zagaja GP; Shalhav AL; Zorn KC
J Urol; 2008 Dec; 180(6):2436-40. PubMed ID: 18930486
[TBL] [Abstract][Full Text] [Related]
32. Prediction of extracapsular extension of prostate cancer based on systematic core biopsies.
Tarján M; Tot T
Scand J Urol Nephrol; 2006; 40(6):459-64. PubMed ID: 17130097
[TBL] [Abstract][Full Text] [Related]
33. Pathological outcomes and biochemical progression in men with T1c prostate cancer undergoing radical prostatectomy with prostate specific antigen 2.6 to 4.0 vs 4.1 to 6.0 ng/ml.
Makarov DV; Humphreys EB; Mangold LA; Walsh PC; Partin AW; Epstein JI; Freedland SJ
J Urol; 2006 Aug; 176(2):554-8. PubMed ID: 16813888
[TBL] [Abstract][Full Text] [Related]
34. Prostate cancer detection rate in patients with repeated extended 21-sample needle biopsy.
Campos-Fernandes JL; Bastien L; Nicolaiew N; Robert G; Terry S; Vacherot F; Salomon L; Allory Y; Vordos D; Hoznek A; Yiou R; Patard JJ; Abbou CC; de la Taille A
Eur Urol; 2009 Mar; 55(3):600-6. PubMed ID: 18597923
[TBL] [Abstract][Full Text] [Related]
35. Clinical and pathologic outcome after radical prostatectomy for prostate cancer patients with a preoperative Gleason sum of 8 to 10.
Bastian PJ; Gonzalgo ML; Aronson WJ; Terris MK; Kane CJ; Amling CL; Presti JC; Mangold LA; Humphreys E; Epstein JI; Partin AW; Freedland SJ
Cancer; 2006 Sep; 107(6):1265-72. PubMed ID: 16900523
[TBL] [Abstract][Full Text] [Related]
36. [Staging of prostate cancer: value of the combined information of endorectal MRI, biopsy Gleason score, and preoperative PSA level].
Wetter A; Ajdukovic AN; Fliessbach K; Lehnert T; Engl T; Jacobi V; Vogl TJ
Rofo; 2006 Apr; 178(4):385-90. PubMed ID: 16607587
[TBL] [Abstract][Full Text] [Related]
37. Lymphovascular invasion is an independent prognostic factor in prostatic adenocarcinoma.
Cheng L; Jones TD; Lin H; Eble JN; Zeng G; Carr MD; Koch MO
J Urol; 2005 Dec; 174(6):2181-5. PubMed ID: 16280760
[TBL] [Abstract][Full Text] [Related]
38. The percentage of positive biopsy cores as a predictor of disease recurrence in patients with prostate cancer treated with radical prostatectomy.
Antunes AA; Srougi M; Dall'Oglio MF; Crippa A; Campagnari JC; Leite KR
BJU Int; 2005 Dec; 96(9):1258-63. PubMed ID: 16287441
[TBL] [Abstract][Full Text] [Related]
39. PCA3 score before radical prostatectomy predicts extracapsular extension and tumor volume.
Whitman EJ; Groskopf J; Ali A; Chen Y; Blase A; Furusato B; Petrovics G; Ibrahim M; Elsamanoudi S; Cullen J; Sesterhenn IA; Brassell S; Rittenhouse H; Srivastava S; McLeod DG
J Urol; 2008 Nov; 180(5):1975-8; discussion 1978-9. PubMed ID: 18801539
[TBL] [Abstract][Full Text] [Related]
40. Preoperative prediction of final pathological features is not improved by the free-to-total prostate-specific antigen ratio in Japanese men with clinically localized prostate cancer.
Miyake H; Sakai I; Harada K; Hara I; Eto H
Int J Urol; 2005 Feb; 12(2):182-6. PubMed ID: 15733113
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
